Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury - 26/08/11
Abstract |
Objectives |
To determine the effect of cyclosporine and rapamycin administration on renal function after ischemia/reperfusion injury (I/R). Cyclosporine A has known nephrotoxic effects. Thus, cyclosporine therapy subsequent to I/R injury may further exacerbate graft dysfunction. Rapamycin is a newer agent that suppresses the immune system by a different mechanism.
Methods |
Male Wistar rats (250 g) were anesthetized, and the suprarenal aorta was clamped for 40 minutes. The right kidney was removed. After recovery, the rats were divided into four groups: group 1, controls, no ischemia and no treatment (n = 10); group 2, ischemia with no treatment (n = 8); group 3, ischemia plus rapamycin (0.17 mg/kg/day gavage, n = 8); and group 4, ischemia plus cyclosporine A (30 mg/kg/day intraperitoneally, n = 9). The glomerular filtration rate was measured 5 to 7 days after I/R injury using urinary iohexol clearance. Data are expressed as the mean ± SEM, and intergroup comparisons were made using one-way analysis of variance.
Results |
The mean GFR value for the controls (no ischemia, no treatment) was 1.23 ± 0.08 mL/min; for group 2 (ischemia, no treatment), it was 1.05 ± 0.10 mL/min; for group 3 (ischemia plus rapamycin) 1.06 ± 0.14 mL/min; and for group 4 (ischemia plus cyclosporine A) 0.44 ± 0.06 mL/min (P <0.05 versus the other three groups). The mean arterial pressure was significantly lower in the ischemic rats treated with cyclosporine A (P <0.05 versus the other three groups).
Conclusions |
After I/R injury, rapamycin may preserve renal function compared with cyclosporine treatment, because it does not have a direct vasoconstrictor effect on the renal microcirculation.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by the Donald Seldin, M.D. Young Investigator Grant of the National Kidney Foundation. |
Vol 62 - N° 4
P. 750-754 - octobre 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
